DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery

Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Epiretinal Membrane

Intervention: Nepafenac 0.1% (Drug); BSS (Other)

Phase: Phase 4

Status: Completed

Sponsored by: Alcon Research


The purpose of this study is to compare the macular volume of patients treated with a 3-month course of topical Nepafenac (0. 1% solution) to patients treated with a placebo course following epiretinal membrane surgery.

Clinical Details

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Primary outcome: Macular thickness

Secondary outcome: Visual Acuity


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- 18 year of age or older, of any race and either sex.

- Able to understand and sign an informed consent that has been approved by an

Institutional Review Board.

- Must agree to comply with study visit schedule and other study requirements.

- Must have vision loss associated with idiopathic epiretinal membrane and secondary

retinal edema.

- Must have pre-operative central foveal thickness greater than 300 microns.

- Prior cataract surgery must be at least 6 months postoperative.

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Vision loss associated with maculopathies other than idiopathic epiretinal membrane

and secondary retinal edema (e. g. branch retinal vein occlusion, central retinal vein occlusion, wet macular degeneration, diabetic retinopathy, posterior uveitis).

- Dry macular degeneration (drusen) with central geographic atrophy.

- Concomitant cataract surgery performed at the time of study vitrectomy.

- Prior vitrectomy surgery in the study eye(s).

- Prior macula laser treatment in the study eye(s).

- Prior periocular steroid injections in the study eye(s) within preceding 6 months.

- Prior cataract surgery in the study eye(s) within the last 6 months.

- Any systemic or ocular disease or disorder, complicating factors or structural

abnormality that would negatively affect the conduct or outcome of the study.

- Use of topical ocular medications during the study period.

- Antibiotics (systemic or topical) outside of study protocol may not be used within 7

days of preoperative/baseline visit or anytime after this visit for the duration of the study.

- Women of childbearing potential not using reliable means of birth control.

- Women who are pregnant or lactating.

- Enrollment of more than one person per household at the same time.

- Enrollment of the investigator or his or her staff, family members of the

investigator, family members of the investigator's staff, or individuals living in the households of these individuals.

- Participation in any investigational drug or device study within 30 days of entering

this study. Note: Patients may have both eyes enrolled in this study provided that 2nd eye enrollment takes place 30 days after completion of the first eye. Second eye will receive the same study treatment as first eye.

- Other protocol-defined exclusion criteria may apply.

Locations and Contacts

Dan Miller, Cincinnati, Ohio 45242, United States
Additional Information

Starting date: January 2009
Last updated: July 27, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017